glp-1 medications covered by insurance MCT2D Patients Face New Barriers for

The GLP-1 receptor agonist market size was exhibited at USD 36.95 billion in 2023 and is projected to hit around USD 261.19 billion by 2033, growing at a CAGR of 21.6% during the forecast period 2024 to 2033.

Worldwide, nearly 40% of adults are overweight and 13% are obese

A comprehensive literature search was conducted across the PubMed, Embase, and Google Scholar databases for peer-reviewed articles published from inception through June 15, 2026, focusing on the landmark SURPASS, SURMOUNT, and SUMMIT trial programs, relevant cardiorenal post hoc analyses, emerging body recomposition trials, and real-world cohort-switching protocols

Visit our FAQ for more details on PatchAid products

A large global retrospective cohort study (n=331,863 matched patients

Here is what the evidence says about protecting your bones and muscle on GLP-1 therapy.